Concentrated insulins: the new basal insulins
نویسندگان
چکیده
منابع مشابه
Concentrated insulins: the new basal insulins
INTRODUCTION Insulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also needed. AREAS COVERED This ...
متن کاملCardiovascular effects of basal insulins
Basal insulin is an important component of treatment for both type 1 and type 2 diabetes. One of the principal aims of treatment in patients with diabetes is the prevention of diabetic complications, including cardiovascular disease. There is some evidence, although controversial, that attainment of good glycemic control reduces long-term cardiovascular risk in both type 1 and type 2 diabetes. ...
متن کاملNew Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Although insulin introduced nearly a century ago has saved the lives of countless people with diabetes, improvements of this therapy continue as significant unmet needs remain (1–4). Even persons with type 2 diabetes who, compared with those with type 1 diabetes, exhibit a much more stable, yet disordered, metabolic milieu only achieve an intended HbA1c target of 7% or lower without hypoglycemi...
متن کاملNew insulins and insulin therapy.
The introduction of the so-called 'designer' insulins, the insulin analogues, has offered new opportunities in the clinical management of diabetes. Two additional new entities are close to reaching clinical practice. Linjeta™ (formally called VIAject) is not an analogue but rather a different formulation of human insulin which may give it a more rapid onset of action, potentially even faster th...
متن کاملClinical experience with the new insulins.
CONVENTIONAL insulins contain several impurities such as proinsulin, C-peptide, polymers of insulin (Steiner et al, 1968) and other pancreatic peptides (Bloom et al, 1976). All are immunogenic (Schlichtkrull et al, 1972) and may lead to the development of insulin-binding antibodies in patients using insulin preparations containing them. As a result, some patients develop local skin sensitivity,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2016
ISSN: 1178-203X
DOI: 10.2147/tcrm.s99855